Cases & Deals

  • Home
  • Practices
  • Bellicum Pharmaceuticals establishes global patent portfolio related to CAR-T and other cellular immunotherapies

Share

Bellicum Pharmaceuticals establishes global patent portfolio related to CAR-T and other cellular immunotherapies

February 2019

Client(s) Bellicum Pharmaceuticals, Inc.

Jones Day is representing Bellicum Pharmaceuticals, Inc. in the development and prosecution of global patent portfolios related to cellular immuno-oncology (IO) and immunotherapies, including BPX-601 (PSCA CAR-T) and BPX-603 (Her2 CAR-T) clinical candidates utilizing the Bellicum’s proprietary GoCAR™ technology.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.